Is Medicine Ready for Clinical CRISPR?

Using precision genome editing to treat or prevent human disease may require several leaps of faith.

Written byJohn Parrington
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

OXFORD UNIVERSITY PRESS, AUGUST 2016CRISPR-Cas9 genome editing has the potential to transform medicine in several important ways. First, the technique makes it possible to manipulate genes in a variety of mammals to create models of human health and disease. Previously, only mice could be engineered in this way, but genome editing has made it possible to precisely modify the genomes of almost any mammal.

Because pig hearts or monkey brains are far more similar to their respective human organs than those of mice, this should have a major impact on our ability to understand the genetic basis of heart disease and various mental disorders. But such developments are likely to be controversial because of opposition by some people to experimentation on primates.

Another way that genome editing affects medicine is by facilitating the study of physiological or pathological processes in human cells in culture. Using genome editing to precisely manipulate the genomes of human cells in vitro is making it possible to identify the genes involved in normal human physiology and in various types of human disease. I discuss these and other transformative applications of CRISPR-Cas9 genome editing in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

December 2016

Traffic Cops

The structure and function of nuclear pores

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies